Wall Street brokerages expect Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating) to report $8.31 million in sales for the current quarter, Zacks reports. Three analysts have provided estimates for Alpine Immune Sciences’ earnings. The highest sales estimate is $15.33 million and the lowest is $4.60 million. Alpine Immune Sciences reported sales of $7.19 million in the same quarter last year, which would suggest a positive year over year growth rate of 15.6%. The business is scheduled to announce its next earnings report on Monday, January 1st.
On average, analysts expect that Alpine Immune Sciences will report full-year sales of $66.15 million for the current year, with estimates ranging from $37.00 million to $102.00 million. For the next fiscal year, analysts anticipate that the firm will post sales of $40.07 million, with estimates ranging from $32.00 million to $45.90 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow Alpine Immune Sciences.
Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) last announced its quarterly earnings results on Thursday, May 12th. The biotechnology company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.06). Alpine Immune Sciences had a negative net margin of 139.41% and a negative return on equity of 46.87%.
Shares of Alpine Immune Sciences stock opened at $7.95 on Thursday. The firm has a market cap of $241.11 million, a P/E ratio of -4.47 and a beta of 1.74. The company has a current ratio of 2.58, a quick ratio of 2.58 and a debt-to-equity ratio of 0.02. Alpine Immune Sciences has a 12 month low of $6.00 and a 12 month high of $15.14. The stock’s fifty day moving average price is $8.58 and its 200-day moving average price is $9.94.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Ensign Peak Advisors Inc boosted its holdings in Alpine Immune Sciences by 50.9% in the first quarter. Ensign Peak Advisors Inc now owns 110,017 shares of the biotechnology company’s stock worth $987,000 after acquiring an additional 37,087 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in Alpine Immune Sciences by 70.8% in the first quarter. Goldman Sachs Group Inc. now owns 22,850 shares of the biotechnology company’s stock worth $205,000 after acquiring an additional 9,471 shares in the last quarter. State Street Corp boosted its holdings in Alpine Immune Sciences by 7.1% in the first quarter. State Street Corp now owns 220,621 shares of the biotechnology company’s stock worth $1,979,000 after acquiring an additional 14,609 shares in the last quarter. Paradigm Biocapital Advisors LP acquired a new stake in Alpine Immune Sciences in the first quarter worth about $3,016,000. Finally, Frazier Life Sciences Management L.P. acquired a new stake in Alpine Immune Sciences in the first quarter worth about $37,546,000. 77.00% of the stock is owned by institutional investors and hedge funds.
About Alpine Immune Sciences (Get Rating)
Alpine Immune Sciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases.
- Get a free copy of the StockNews.com research report on Alpine Immune Sciences (ALPN)
- The TJX Companies: It’s Not All Doom And Gloom In Retail
- Simply Good Foods Stock is Simply Looking Good Down Here
- Shoe Carnival’s Q1 Results Are No Joke, Shares Fall 15%
- Dynatrace: Fundamentals are Positive While Being Punished
- Analog Devices Is Ready To Scale New Highs Despite Tech Wreck
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.